<DOC>
	<DOCNO>NCT01290835</DOCNO>
	<brief_summary>The purpose study determine feasible , safe , effective use Cyberknife radiotherapy deliver partial breast radiotherapy lumpectomy.Patients meet eligibility criterion invite participate . Adjuvant radiotherapy deliver use CyberKnife radiotherapy use twice daily session five day total ten session . Short-term long-term toxicity assess well Tumor control site failure ( ) .</brief_summary>
	<brief_title>Conformal Partial Breast Irradiation With CyberKnife After Resection Early Stage Breast Cancer</brief_title>
	<detailed_description>This study determine feasibility toxicity short course accelerate radiotherapy adjuvant treatment early stage breast cancer . Successful completion project may provide rationale offer treatment select patient benefit potentially less tissue damage shorter overall course therapy . These improvement may ultimately allow patient opportunity breast conserve therapy treat cancer</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Diagnosis breast malignancy , stage T1 2 . Surgical treatment lumpectomy 3. age 60 old 4. resection margin negative least 2mm 5. grade 6 . ER positive 7. unicentric 8. invasive ductal 9. pathologic free nodal metastasis ( N0 , i+ ) 10 . Postlumpectomy cavity whole breast ratio must less equal 30 % Exclusion criteria 1 . Prior radiotherapy breast 2 . Neoadjuvant chemotherapy 3. multicentric disease 4 . Pure DCIS histology 5 . Presence extensive intraductal component 6 . Node positive disease ( N1 great )</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Stereotactic radiotherapy</keyword>
	<keyword>CyberKnife follow lumpectomy</keyword>
	<keyword>Breast cancer</keyword>
</DOC>